Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China.
Front Immunol. 2023 Mar 27;14:1118053. doi: 10.3389/fimmu.2023.1118053. eCollection 2023.
Preoperative inflammatory status plays an important role in the prognosis of malignancy. We sought to explore the value of preoperative inflammatory biomarkers in predicting long-term outcomes of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC).
Patients who underwent LT for HCC in our hospital between January 2010 and June 2020 were included in this study. Demographic, clinical, laboratory, and outcome data were obtained. The area under the curve (AUC) of the receiver operating characteristic curve was used to evaluate the predictive value of inflammatory biomarkers. The effectiveness of inflammatory biomarkers in predicting outcomes was analyzed by univariate and multivariate Cox proportional hazards analyses.
A total of 218 patients were included in the study, with a mean age of 53.9 ± 8.5 years. The AUC of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune inflammation index (SII), and systemic inflammatory response index (SIRI) for overall survival (OS) were 0.741, 0.731, 0.756, 0.746, and 0.749, respectively. Cox proportional hazards model indicated that SIRI > 1.25 was independently associated with low OS [hazard ratio (HR) = 2.258, P = 0.024]. PLR > 82.15 and SIRI > 0.95 were independently associated with low disease-free survival (HR = 1.492, P = 0.015; and HR = 1.732, P = 0.008, respectively). In the survival analysis, the prognosis of patients with high preoperative SIRI and PLR was significantly worse (P < 0.001).
SIRI and PLR were useful prognostic markers for predicting patients with HCC after LT.
术前炎症状态在恶性肿瘤的预后中起着重要作用。我们旨在探讨术前炎症生物标志物在预测肝细胞癌（HCC）患者肝移植（LT）后长期结局中的价值。
本研究纳入了 2010 年 1 月至 2020 年 6 月期间在我院接受 LT 治疗的 HCC 患者。获取了人口统计学、临床、实验室和结局数据。受试者工作特征曲线下面积（AUC）用于评估炎症生物标志物的预测价值。采用单因素和多因素 Cox 比例风险分析来分析炎症生物标志物预测结局的有效性。
本研究共纳入 218 例患者，平均年龄为 53.9 ± 8.5 岁。中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、单核细胞与淋巴细胞比值（MLR）、全身免疫炎症指数（SII）和全身炎症反应指数（SIRI）对总生存期（OS）的 AUC 分别为 0.741、0.731、0.756、0.746 和 0.749。Cox 比例风险模型表明，SIRI > 1.25 与较低的 OS 独立相关（风险比[HR] = 2.258，P = 0.024）。PLR > 82.15 和 SIRI > 0.95 与较低的无疾病生存率（HR = 1.492，P = 0.015；和 HR = 1.732，P = 0.008）独立相关。在生存分析中，术前 SIRI 和 PLR 较高的患者的预后明显较差（P < 0.001）。
SIRI 和 PLR 是预测 HCC 患者 LT 后预后的有用标志物。
Zotero 插件
